• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences

    1/29/25 4:15:00 PM ET
    $CERT
    Computer Software: Prepackaged Software
    Technology
    Get the next $CERT alert in real time by email

    RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (NASDAQ:CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2024 after the market close on Wednesday, February 26th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET.

    Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

    Certara also announced that company management will participate in the following investor conferences:

    • Leerink Partners Global Healthcare Conference

      Date and Time: Tuesday, March 11th at 1:00PM ET
    • Barclays 27th Annual Global Healthcare Conference

      Date and Time: Wednesday, March 12th at 11:30AM ET

    Live and archived webcasts of these events will be available on the "Investors" section of the Certara website at https://ir.certara.com/.

    About Certara

    Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

    Investor Relations Contact:

    David Deuchler

    Gilmartin Group

    [email protected]

    Media Contact:

    Alyssa Horowitz

    [email protected]



    Primary Logo

    Get the next $CERT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERT

    DatePrice TargetRatingAnalyst
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    2/27/2025$16.00Buy
    TD Cowen
    9/27/2024$16.00Neutral → Buy
    UBS
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/4/2024Mkt Perform
    JMP Securities
    2/26/2024$19.00Market Perform
    Leerink Partners
    12/7/2023$17.00Neutral
    UBS
    12/5/2023Sector Weight
    KeyBanc Capital Markets
    More analyst ratings